Virtual ribbon cutting and tour featured remarks from New Jersey Governor Phil Murphy, FDA’s Peter Marks, as well as panel discussions with industry leaders from ARM, NIIMBL, Century Therapeutics, BioNJ, NJEDA, NJIT and NJII on the rise of Cell & Gene Therapy in New Jersey.
Thrive Bioscience Launches the CellAssist to Provide Imaging, Analytics, and Documentation for Reproducible Cell Culture
WAKEFIELD, Mass., Oct. 5, 2020 — Thrive Bioscience introduces the CellAssist® which enables cell culture researchers to image, analyze, and document all cells, plates, reagents, and workflow details in a centralized database. The CellAssist was developed by Thrive Bioscience, an innovator in cell culture systems, in collaboration with several highly-regarded academic institutions. [Read more…]
TreeFrog Therapeutics Awarded the Galien MedStartup Prize for its International Consortium on iPSC Quality with US, Japan & France
The Prix Galien MedStartup was awarded on October 26th in Boston to the French cell therapy biotech TreeFrog Therapeutics in the category “Biopharmaceutical Industry”
Organized by the prestigious Galien Foundation and Business France, the Prix Galien MedStartup rewards the best Franco-American collaborations in the pharmaceutical sector.
TreeFrog Therapeutics received this award for the QC-Stem International Consortium, which brings together world-class experts in induced pluripotent stem cell (iPSC) quality from the Harvard Stem Cell Institute and the Dana-Farber Cancer Institute in Boston (USA), the FBRI in Kobe (Japan) and the Imagine Institute in Paris (France).
BioStem Technologies, Inc. Announces Launch of AEON™
BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced the launch of AEON™, the 6th and newest addition to the Company’s perinatal tissue allograft platform.
AEON™ is an all-natural amniotic fluid allograft, aseptically processed and then terminally sterilized using e-beam irradiation. The Company’s newly developed proprietary fluid processing technique has resulted in an allograft that does not require any preservative solutions to maintain the fundamental natural components which activate paracrine signaling. This lack of preservatives results in a pure natural fluid, free from dilution of the many growth factors, cytokines, proteins, and other naturally occurring nutrients present. [Read more…]
Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure
MIAMI, Oct. 20, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network (“RCN”). Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF. [Read more…]
